FDA Grants Breakthrough Therapy for Praxis' Elsunersen, Citing 77% Seizure Reduction in Rare Epilepsy
PRAX has more than doubled off its 52-week low of $37.19.
Summary
Praxis Precision Medicines received FDA Breakthrough Therapy Designation for elsunersen, its drug for SCN2A-DEE, a rare and severe genetic epilepsy. This designation was based on positive EMBRAVE Part A trial results, which showed a 77% sham-adjusted reduction in monthly seizures and broad improvements in pediatric patients. The BTD enables expedited development and regulatory review, and the pivotal EMBRAVE3 study is already enrolling under a streamlined, single-arm pathway. This is a significant positive development, following the company's announcement of positive elsunersen trial results in April and a recent setback with its vormatrigine candidate in June. The designation highlights the drug's strong potential to be the first disease-modifying therapy for this condition, which currently lacks approved treatments. The ongoing EMBRAVE3 study will be key to watch for further progress.
At the time of this announcement, PRAX was trading at $282.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $37.19 to $366.52. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.